Vantas Valera Pharmaceuticals - Treatment for Prostate Cancer
Vantas is a long-acting implant designed for the continuous 12-month administration of histrelin, a synthetic nonapeptide agonist of luteinizing hormone-releasing hormone (LHRH). Vantas is indicated for the palliative treatment of advanced prostate cancer.Posted: October 2004
Vantas (histrelin) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
